Summer is a busy time for everyone, guests and listeners alike, so today we're taking stock. This is our Summer Recap — a clips episode pulling together the best moments from conversations you might have missed over the past few months.

We'll hear from Randy Teel of Arvinas and Per Lundin of Evox on two very different ways of getting drugs to the brain, and Laurent Lévy of Nanobiotix on outsmarting the liver altogether. We'll meet the founders behind these companies, including Andy Parker of Step Pharma and Gene Mack of Gain Therapeutics, and the unlikely paths that got them there. We'll dig into the science of nonsense mutations with Nerissa Kreher of Alltrna, circular RNA with Lu Gao of Therorna, and a cancer target hiding in human genetics. And we'll close with what these leaders think success actually looks like, years from now.

So sit back, and let's revisit some of our favourite moments from the summer.

• 02:32 Solving the delivery problem
• 08:39 Founder journeys
• 15:13 Platform science
• 24:41 Business, money, and geopolitics
• 32:28 Looking ahead

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter

To dive deeper into the topic: 

• Episode 204: The first PROTAC is here. What comes next in protein degradation?
• Episode 205: Turning cancer cell dependencies into targeted therapies
• Episode 208: Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson's
• Episode 209: Why Western pharma is sleeping on China's circular RNA revolution
• Episode 211: Beyond biology: Nanobiotix's physics-first approach to cancer
• Episode 213: How Evox Therapeutics is targeting CNS diseases with exosomes
• Episode 214: Rewriting the rules of genetic medicine with tRNA therapeutics